Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials

Published:2018-11-22 Issue:2 Volume:33 Page:333-339
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Langley R.G.¹,Kimball A.B.²,Nak H.³,Xu W.⁴,Pangallo B.⁴,Osuntokun O.O.⁴,Agada N.⁴,Reich K.⁵

Affiliation:

1. Dalhousie University Faculty of Medicine; Halifax NS Canada

2. Massachusetts General Hospital; Boston MA USA

3. The Jikei University, School of Medicine; Tokyo Japan

4. Eli Lilly and Company; Indianapolis IN USA

5. Dermatologikum Berlin and SCIderm Research Institute; Hamburg Germany

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.15242/fullpdf

Reference27 articles.

1. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A;Liu;J Inflamm Res,2016

2. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials;Griffiths;Lancet,2015

3. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis;Gordon;N Engl J Med,2016

4. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study;Reich;Br J Dermatol,2017

5. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data;Strober;J Am Acad Dermatol,2017

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer;BMJ Case Reports;2024-08

2. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

3. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials;Arthritis Research & Therapy;2024-02-12

4. Psoriasis comorbidity management in the COVID era: a pressing challenge;Frontiers in Microbiology;2023-11-10

5. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3